DEMENTIAS--INDIANAPOLIS-IBADAN COMPARATIVE PREVALENCE

Project: Research project

Description

It is the intent of this study to compare the Age Specific
Prevalence and Incidence of dementing disorders, especially Alzheimer's
disease in a sample, both community and nursing home dwelling, of
Afro-Americans age 65 years and over living in Indianapolis, Indiana
(n=2500) and a sample of Nigerians age 65 years and over living in Ibadan
(n=2500); to compare the neuropathology of aging and of Alzheimer's disease
and other dementing disorders in elderly Nigerian Africans and Indianapolis
AfroAmericans; and to conduct a case control and a prospective study of
risk factors of Alzheimer's disease in the two communities in association
with the World Health Organization multi-centered studies. The WHO has
recently initiated a cross national multi-centered etiology oriented study
and have selected six sites including Ibadan and Indianapolis to
participate in this study. The research design for the prevalence study will follow a
two-stage design in which there is an initial screening interview followed
by a clinical evaluation on a subset of the subjects who were screened.
There will be an interim follow-up of dementia cases and questionable cases
one year later, to document course in cases and to determine diagnosis in
the questionable cases. The incidence study will be carried out two years
after the prevalence study and will replicate the methods of the prevalence
study. All subjects who die during the course of the study will be
eligible for neuropathological evaluation, for studies of the aging normal
brain, and to confirm diagnosis in demented patients. While the evidence accumulates that there is a genetic basis for
at least a proportion of patients with DAT, most researchers conclude that
environmental risk factors also play a major role in etiology. The
establishment of different prevalence and incidence of DAT in different
populations would greatly aid the search for these risk factors.
StatusFinished
Effective start/end date7/1/918/31/12

Funding

  • National Institutes of Health
  • National Institutes of Health: $1,123,542.00
  • National Institutes of Health
  • National Institutes of Health: $572,201.00
  • National Institutes of Health: $1,423,573.00
  • National Institutes of Health: $1,001,527.00
  • National Institutes of Health: $215,480.00
  • National Institutes of Health: $39,955.00
  • National Institutes of Health: $1,348,942.00
  • National Institutes of Health: $1,066,641.00
  • National Institutes of Health: $1,597,999.00
  • National Institutes of Health: $595,020.00
  • National Institutes of Health: $1,146,631.00
  • National Institutes of Health: $35,675.00
  • National Institutes of Health: $872,560.00
  • National Institutes of Health: $54,950.00
  • National Institutes of Health: $123,549.00
  • National Institutes of Health: $48,214.00
  • National Institutes of Health: $1,597,448.00
  • National Institutes of Health
  • National Institutes of Health: $1,322,396.00
  • National Institutes of Health: $939,017.00
  • National Institutes of Health
  • National Institutes of Health: $1,013,909.00
  • National Institutes of Health: $933,797.00

Fingerprint

Dementia
Alzheimer Disease
African Americans
Apolipoproteins E
Incidence
Cross-Sectional Studies
Nursing Homes
Cohort Studies
Alleles
Independent Living
Research Design
Research Personnel
Prospective Studies
Interviews
Population
Genotype
Haplotypes
Natural History

ASJC

  • Medicine(all)